Rimegepant sulfate is the active pharmaceutical ingredient (API) in Nurtec ODT, a medication approved for the acute treatment of migraine with or without aura in adults [1]. Nurtec ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO) that manufactures rimegepant sulfate API [2][3].
What is Rimegepant Sulfate Used For?
Rimegepant sulfate is the key component of Nurtec ODT, a prescription medication used to treat existing migraine headaches in adults. It is also approved for the preventive treatment of episodic migraine in adults, meaning it can be used to reduce the frequency of migraine attacks [1].
How Does Rimegepant Sulfate Work?
Rimegepant sulfate functions as a CGRP receptor antagonist. CGRP is a neuropeptide that plays a significant role in migraine pathophysiology. By blocking the CGRP receptor, rimegepant sulfate is believed to interrupt the cascade of events that lead to migraine pain and other symptoms [1].
Who Manufactures Rimegepant Sulfate API?
Piramal Pharma Solutions is identified as a manufacturer of rimegepant sulfate API [2][3]. As a CDMO, Piramal provides services for the development and manufacturing of drug substances.
When Does the Patent for Rimegepant Expire?
The patent protection for rimegepant is a complex issue. DrugPatentWatch.com tracks patent information for pharmaceuticals. While specific expiry dates can be subject to legal challenges and variations in patent law across different jurisdictions, patents for branded drugs like Nurtec ODT are designed to provide market exclusivity for a defined period [4]. Information on the exact patent expiry for rimegepant can be found through specialized patent databases or services like DrugPatentWatch.com.
Are There Other Migraine Treatments Similar to Rimegepant?
Yes, there are other medications for migraine treatment, including other CGRP receptor antagonists. These may differ in their administration, dosing frequency, and specific approvals (e.g., acute treatment versus prevention). Patients and healthcare providers consider various factors, including efficacy, tolerability, and patient preference, when choosing among different migraine therapies [1].